Impact News +++ NACHBÖRSE/XDAX +0,2% auf 24.394 Pkt - Viromed brechen ein (Dow Jones) +++ VIROMED Aktie +10,24%

MESOBLAST Aktie

>MESOBLAST Aktienkurs

1.276 EUR 0.0% (TradegateBSX)

Ask: 1.276 EUR / 5133 Stück

Bid: 1.206 EUR / 1660 Stück

Tagesumsatz: 6944 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

MESOBLAST Aktie über LYNX handeln

Intraday

1 Jahr

>MESOBLAST Performance

1 Woche: -1,1%

1 Monat: +0,9%

3 Monate: -1,1%

6 Monate: -0,3%

1 Jahr: +28,9%

laufendes Jahr: -15,2%

>MESOBLAST Aktie

Name:

MESOBLAST LTD.

Land:

Australien

Sektor:

Gesundheit

ISIN/ Wkn:

AU000000MSB8 / A0DNPW

Symbol/ Ticker:

LWB (Frankfurt)

Kürzel:

FRA:LWB, ETR:LWB, LWB:GR

Index:

Webseite:

https://www.mesoblast.com..

Profil:

Mesoblast Limited is a biotechnology company specializing in the development of allogeneic, or off-the-shelf, cellular medicines intended for the treatment of severe and life-threatening inflammatory conditions. Leveraging a proprietary technology pl..
>Volltext..

Marktkapitalisierung:

1597.72 Mio. EUR

Unternehmenswert:

1602.1 Mio. EUR

Umsatz:

56.89 Mio. EUR

EBITDA:

-56.76 Mio. EUR

Nettogewinn:

-83.08 Mio. EUR

Gewinn je Aktie:

-0.06 EUR

Schulden:

114.73 Mio. EUR

Liquide Mittel:

110.35 Mio. EUR

Operativer Cashflow:

-62.26 Mio. EUR

Bargeldquote:

1.01

Umsatzwachstum:

1011.51%

Gewinnwachstum:

10.99%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

MESOBLAST

Letzte Datenerhebung:

09.05.26

>MESOBLAST Kennzahlen

Aktien/ Unternehmen:

Aktien: 1292.82 Mio. St.

Frei handelbar: 65.15%

Leerverk. Aktien: -

Rückkaufquote: -9.51%

Mitarbeiter: 81

Umsatz/Mitarb.: 0.18 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 95.62%

Bewertung:

KGV: -

KGV lG: -

KUV: 27.85

KBV: 3.4

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 48.65%

Gewinnmarge: -146.03%

Operative Marge: -113.08%

Managementeffizenz:

Gesamtkaprendite: -13.17%

Eigenkaprendite: -18.27%

>MESOBLAST Peer Group

Gesundheit, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten, Herz-Kreislauf- Behandlung/ Kardiologie

>MESOBLAST Chart & Kurs - Tradegate

>MESOBLAST News

02.05.26 - 16:48	Buy, hold, sell: Mesoblast, Mineral Resources, and Woolworths shares (Fool)
	Analysts have given their verdict on these shares. Let's see what they are saying. The post Buy, hold, sell: Mesoblast, Mineral Resources, and Woolworths shares appeared first on The Motley Fool Australia....

30.04.26 - 06:48	Mesoblast reports Q1 results (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

30.04.26 - 03:00	Mesoblast shares: Cash burn falls and Ryoncil® sales climb (Fool)
	Mesoblast reports higher Ryoncil® sales, improved cash management, and research milestones for the March 2026 quarter. The post Mesoblast shares: Cash burn falls and Ryoncil® sales climb appeared first on The Motley Fool Australia....

30.04.26 - 02:57	Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million (GlobeNewswire EN)
	Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain...

29.04.26 - 04:00	A big milestone for this ASX biotech. Here′s why the share price is moving (Fool)
	Mesoblast hits a key trial milestone... The post A big milestone for this ASX biotech. Here's why the share price is moving appeared first on The Motley Fool Australia....

29.04.26 - 02:57

Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain (GlobeNewswire EN)

NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase 3 clinical trial evaluating rexlemestrocel-L for the treatment of chronic low back pain (CLBP) associated with degenerative disc disease has achieved its patient recruitment target. This marks a significant milestone in Mesoblast's plans for commercialization of rexlemestrocel-L, its proprietary allogeneic stromal cell therapy targeting inflammatory processes underlying disc degeneration....

29.04.26 - 02:24	Mesoblast shares in focus after key Phase 3 milestone for low back pain (Fool)
	Mesoblast shares are in focus after reaching a major patient recruitment milestone in its pivotal Phase 3 trial for chronic low back pain. The post Mesoblast shares in focus after key Phase 3 milestone for low back pain appeared first on The Motley Fool Australia....

16.04.26 - 04:48	Down almost 20% this year, how high could Mesoblast shares go? (Fool)
	The forward pipeline is looking promising. The post Down almost 20% this year, how high could Mesoblast shares go? appeared first on The Motley Fool Australia....

15.04.26 - 16:27	Mesoblast gains on licensing deal for CAR technology platform (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

15.04.26 - 07:48	Why are Mesoblast shares jumping 8% today? (Fool)
	The biotech star has announced an exciting acquisition on Wednesday. The post Why are Mesoblast shares jumping 8% today? appeared first on The Motley Fool Australia....

15.04.26 - 06:24	Why Evolution Mining, Mesoblast, Nufarm, and Virgin Australia shares are storming higher today (Fool)
	These shares are having a good session on hump day. But why? The post Why Evolution Mining, Mesoblast, Nufarm, and Virgin Australia shares are storming higher today appeared first on The Motley Fool Australia....

15.04.26 - 02:12

Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products (GlobeNewswire EN)

NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has acquired an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform for precision-enhanced augmentation of therapeutic mesenchymal lineage stromal cell (MSC) products. Mesoblast plans to incorporate the engineered CARs to further boost effectiveness of Mesoblast's products, with the goal of enhancing the target specificity and augmenting inherent properties of immunomodulation and tissue regeneration....

10.04.26 - 22:12	Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION (GlobeNewswire EN)
	Working with Parent Project Muscular Dystrophy and the Duchenne Registry on patient identification and trial awareness efforts ...

10.04.26 - 06:12	Why Amaero, Mesoblast, Telix, and Tivan shares are charging higher today (Fool)
	These shares are ending the week on a high. But why? The post Why Amaero, Mesoblast, Telix, and Tivan shares are charging higher today appeared first on The Motley Fool Australia....

08.04.26 - 15:12	Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation (GlobeNewswire EN)
	Mesoblast outlines commercial strategy to double net revenues as Ryoncil® approaches US$100M net revenue milestone since launch last year...

08.04.26 - 13:33	Mesoblast gains as FDA clears study to test Ryoncil in Duchenne (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

08.04.26 - 05:36	Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy (GlobeNewswire EN)
	Partnering with Parent Project Muscular Dystrophy to ensure timely access to the trial for eligible patients...

07.04.26 - 17:18	Mesoblast drops after Ryoncil sales data for March quarter (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

07.04.26 - 08:12	Why Challenger, Lotus Resources, Mesoblast, and Wildcat shares are falling today (Fool)
	These shares are starting the week in the red. But why? The post Why Challenger, Lotus Resources, Mesoblast, and Wildcat shares are falling today appeared first on The Motley Fool Australia....

07.04.26 - 04:36	Mesoblast shares are back in the red on Tuesday. Here′s why (Fool)
	Mesoblast shares slip despite another strong quarterly sales update from Ryoncil. The post Mesoblast shares are back in the red on Tuesday. Here's why appeared first on The Motley Fool Australia....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Noli me tangere! - Rühr mich nicht an! - Neues Testament: Evangelium nach Johannes

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram